


Asselah T, Hassanieh T, Qadish RB, al. et. A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis. Journal of Hepatology. 2015;62(S861).


Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV [Internet]. Department of Health and Human Services; 2017 [cited Accessed June 13, 2019].


Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-

prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int.

Flamm SL, Bacon B, Curry MP, et al. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C:


Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, et al. Factors that determine the development and

or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016;22(4):446-458.

Ford MM, Johnson N, Desai P, Rude E, Laraque F. From care to cure: demonstrating a model of clinical patient navigation


Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after


HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol.
2015;63(3):564-572.

genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label,


Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis,


German P, Pang P, West S, Han LL, Sajwani K, Mathias A. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [abstract 06]. Presented at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; May 19-21; Washington DC. 2014;.


Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs


Lange B, Roberts T, Cohn J. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis. 2017;17(Suppl 1):693.


Lawitz EJ, Gane EJ, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 wks vs 18 wks of treatment w/ GRZ and ELB w/ or without RBV for HCV GT1 infection in previously untreated pts w/ cirrhosis and pts w/ previous null response w/ or without cirrhosis (C-WORTHY), randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075-86.


Modi AA, Nazario H, Trotter JF, et al. Safety and efficacy of Simeprevir plus sofosbuvir with or without Ribavirin in patients


Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with endstage renal disease on haemodialysis or GFR


Neate R. Welcome to Jail Inc: how private companies make money off US prisons. The Guardian. 2016;


Newsum AM, Stolte IG, van der Meer JTM. Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM). Euro Surveill. 2017;22(21):30540.


Reau N, Kwo PY, Rhee S. MAGEllAN-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1-6 Infection. In EASL International Liver Meeting, April. 2017.


Selph S, Chou R. Impact of contacting study authors on systematic review conclusions: diagnostic tests for hepatic fibrosis. 2014.


Terrault NA, McCaughan GW, Curry MP, Gane E, Fagioli S, Fung JYY, et al. International Liver Transplantation Society


Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS. 2011;25(7):967-975.

Tice JA, Chahal HS, Ollendorf DA. Comparative clinical effectiveness and value of novel interferon-free combination therapy for hepatitis C genotype 1 summary of California technology assessment forum report. JAMA Internal Medicine. 2015;175(9):1559-1560.


U.S. Congressional Budget Office. Prescription drug pricing in the private sector. 2015.


